Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
    • AGM Invitations
    • IPOs
  • inderesTV
  • Portfolio
  • Forum
  • Discovery
  • Q&A
  • About Us
    • Our Coverage
    • Team
Press release

Revenio to arrange a press conference on the Visionix acquisition today April 13, 2026 at 2.00 p.m.

Revenio Group

Revenio Group Corporation | Press Release | April 13, 2026 at 09:45:00 EEST

Revenio is to arrange a webcast and teleconference call for analysts, media, and investors in English today, on April 13, 2026, at 2.00 p.m. (EEST) on the acquisition announced today at 9.30 a.m. (EEST).

The press conference will be presented by CEO Jouni Toijala and CFO Robin Pulkkinen, followed by a discussion participated by Revenio’s Chair of the Board Arne Boye Nielsen, Caravelle Capital’s Managing Partner Charles Vilgrain, and Visionix’s CEO Marc Abitbol.

Anyone can follow the event via a live webcast at https://event.videosync.fi/investor-event

Questions can be placed through the webcast chat function or by phone. To ask questions by phone, the participant is required to register at https://player.videosync.fi/event/investor-event/dial-in

After the registration, you will be provided with a phone number, user ID, and a conference ID to access the conference. To ask a question, press *5 on your telephone keypad to enter the queue.

A recording of the webcast will be published on www.reveniogroup.fi/en/ after the event.

For further information, please contact
Robin Pulkkinen, CFO, tel. +358 50 505 9932
robin.pulkkinen@revenio.fi

Distribution
Key media
www.reveniogroup.fi/en

Revenio Group in brief
Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, microperimeters, and perimeters as well as software solutions under the iCare brand.

In 2025, the Group’s net sales totaled EUR 109.7 million, with an operating profit of EUR 25.4 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Attachments


Revenio to arrange a press conference on the Visionix acquisition today April 13, 2026 at 2.00 p.m.

Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.